an antipyretic analgesic agent also known as acetaminophen in the USA
1st synthesised in 1877
extensive use commenced around 1947, initially as prescription only in USA
OTC status gained in 1960 in USA
toxic effects 1st noted in 1971
pharmacology:
rapidly absorbed from GIT - peak concentration 60-120mins if tablet or capsule form ingested
Vd 1.0-2.0L/kg
half life 1-3hrs but may increase to 17hrs in liver disease
metabolised by liver:
52% by sulphation
42% by glucuronidation
2% excreted unchanged in urine
4% biotransformed by C-P450 MFO system
but in overdose when glutathione stores are depleted, N-acetyl-p-benzoquinoneimine (NAPQI) accumulates and causes hepatocellular necrosis
actions
antipyretic analgesic
its analgesic actions appear to require CB1 receptors 1)
a secondary metabolite N-arachidonoylaminophenol (AM404) of paracetamol has multiple effects on cannabinoid signaling including blockade of anandamide uptake; inhibition of fatty acid amide hydrolase (FAAH), an enzyme that metabolizes the eCB arachidonoylethanolamine (anandamide); and indirect activation of TRPV110 and/or cannabinoid receptors.
inhibits diacylglycerol lipase synthesis of 2-arachidonoyl glycerol (2-AG) which makes one of the endogenous cannabinoids resulting in reduced CB1 activation which may have a role in nociception 2)
even normal doses may cause fatal liver failure if prolonged in susceptible patients (eg. malnourished or those with liver disease)
for example, see:
here (MJA 2007) for a fatal case where a 45yr old lady was ordered 1g paracetamol qid strictly for 8 days whilst nil by mouth for an abdominal surgical condition.